Page 7 - Tim Dyer News Today

Addex Therapeutics Ltd: Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021 1 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Chief Executive Officer, Tim Dyer, will present at Access to Giving Virtual Conference at 9 AM ET on July 14, 2021. Mr. Dyer will give a corporate update, including an overview of recent advances in Addexs clinical trial p...

Addex Therapeutics Ltd: Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators Data could enable acceleration of lead optimization using computer aided drug discovery tools Addex existing mGlu2 positive allosteric modulator, ADX71149, in clinical studies for epilepsy and mGlu2 negative allosteric modulators in preclinical development for neurocognitive disorders Ge 2 1 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clini...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia ... Addex TherapeuticsJune 29, 2021 GMT Geneva, Switzerland, June 29, 2021 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that screening of patients has started for its pivotal Phase ...

First patients enrolled into multi-center U.S. study Geneva, Switzerland, June 7, 2021 -- Addex Therapeutics... | June 7, 2021

First patients enrolled into multi-center U.S. study Geneva, Switzerland, June 7, 2021 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering

Message : Required fields Geneva, Switzerland, May 24, 2021 -- Addex Th https://www.globenewswire.com/Tracker?data=GKEDSALQ3NE4EtVCK9RzLXOk8Q1WB4CkSAscPRzRqf0SdKsQfRwX9gF3D5OianoM6yqhedJ0aWDLbl85uBW8pGIBsUsozfgyWuKSHEalz5Y= e https://www.globenewswire.com/Tracker?data=_w0gykO1cRWXvNInzg_3desjb1_u59TFS0A9iWd0zSqOojFGKcGUUTA-pVC88i-7tgLyk1ZFhlOA_qCsbfnT9w== rapeutics https://www.globenewswire.com/Tracker?data=Hs_rkfRwMjZ7W-Q8M7njxKHxgbDMLkKODX_R98HbsH48L3DiAk0zV907yb2MqLBez4xLV5rL_mMX9NC-...

2 1 – Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, will participate at the virtual Benchmark Company Healthcare House Call Conference on May 26 th, 2021 (09:00 – 16:30 EDT) Mr. Dyer will be available for virtual one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting with management, plea...

Addex Therapeutics Ltd: Addexs Dipraglurant Restores Synaptic Plasticity in Models of Dystonia important 2 1 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that dipraglurant was able to rescue long-term impairment of synaptic plasticity in two well validated models of dystonia. The data were published in the journal, Neuropharmacology, under the title "Rescue of st...

Nassau-DE, the Local Campaign Organization of the Marine Toys for Tots Foundation, recently announced the appointment of its new coordinator. James “Jim” DeMartino has been confirmed by the national Toys for Tots foundation as replacement for Bob...

Financial Summary: Income remained stable in the first quarter 2021 compared to the first quarter 2020 and related primarily to amounts received under our funded research collaboration with Indivior. R&D expenses decreased by CHF 0.8 million to CHF 2.7 million in the first quarter 2021 compared to CHF 3.6 million in the first quarter 2020, primarily due to the postponement of the start of our dipraglurant phase 2b/3 PD dyskinesia clinical trial. Research and development expenses consist primar...